• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ: NAMS )

    18.46 -0.35 (-1.86%)
    Streaming Delayed Price Updated: 2:40 PM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 342,720
    Open 18.57
    Bid (Size) 18.44 (4)
    Ask (Size) 18.56 (2)
    Prev. Close 18.81
    Today's Range 18.15 - 20.00
    52wk Range 5.633 - 26.35
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
    -- Company expects to report topline data in the first quarter of 2025 -- 
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire

    Performance

    YTD
    +54.48%
    +54.48%
    1 Month
    +3.48%
    +3.48%
    3 Month
    -7.93%
    -7.93%
    6 Month
    +10.21%
    +10.21%
    1 Year
    +54.48%
    +54.48%

    More News

    Read More
    What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
    Via Investor's Business Daily
    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
    From NewAmsterdam Pharma N.V
    Via GlobeNewswire
    NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
    From NewAmsterdam Pharma N.V
    Via GlobeNewswire
    NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
    From NewAmsterdam Pharma N.V
    Via GlobeNewswire
    NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
    From NewAmsterdam Pharma N.V
    Via GlobeNewswire
    NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
    From NewAmsterdam Pharma N.V
    Via GlobeNewswire
    NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
    From NewAmsterdam Pharma N.V
    Via GlobeNewswire
    NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
    From NewAmsterdam Pharma N.V
    Via GlobeNewswire
    NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
    From NewAmsterdam Pharma N.V
    Via GlobeNewswire
    NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    From NewAmsterdam Pharma N.V
    Via GlobeNewswire
    World Acceptance Posts Upbeat Earnings, Joins Kaman, Spirit Airlines And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Cholesterol Player NewAmsterdam Pharma's Obicetrapib Is A Potential Blockbuster In Cardiovascular Market: Bullish Analyst Says
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.